Provisional figures on participation in the National Immunisation Programme According to RIVM’s registration system, at least 90% of babies have been vaccinated against mumps, measles and rubella (MMR).
Proposed European PFAS ban officially submitted The Netherlands, Germany, Denmark, Sweden and Norway today took the first formal step towards a European ban on per- and polyfluoroalkyl substances (PFAS) by jointly submitting a restriction proposal to the European Chemicals Agency (ECHA).
More than two million invitations to get vaccinated against HPV in 2023 In early 2023, 1.3 million young adults will receive an invitation to get vaccinated against the human papillomavirus (HPV). This group comprises around 900,000 men and 400,000 women between the ages of 19 and 27.
Incidence of infections that cause gastrointestinal symptoms on the rise again In 2021, the incidence of enteric infections – which mainly cause gastrointestinal symptoms – was higher than in 2020, but still lower than before the coronavirus pandemic. This is the outcome of a study into enteric infections and pathogens transmitted from animals to humans.
PFAS levels in drinking water from river water need to be brought down The National Institute for Public Health and the Environment (RIVM) advises to reduce PFAS concentrations in the drinking water in parts of the Netherlands in the coming years. This concerns drinking water produced from river water.
Cancer screening programmes now more accessible to transgender and intersex persons Since October 2022, is it has become easier for transgender and intersex persons to take part in cervical cancer screening and breast cancer screening. Transgender and intersex persons with a uterus and/or breast tissue can register with Bevolkingsonderzoek Nederland.
Almost half of 9 and 10-year-olds get HPV vaccination at first opportunity This spring, more than 800,000 young people received an invitation to be vaccinated against HPV, the human papillomavirus.
Side effect reports National Immunisation Programme 2021 Last year, the Netherlands Pharmacovigilance Centre Lareb received 1,462 reports of possible side effects from vaccines administered under the National Immunisation Programme. As was the case in previous years, no new, disconcerting side effects have
Participation in National Immunisation Programme shows slight decrease Participation in the National Immunisation Programme has fallen slightly, showing a decrease of 1 to 2 percentage points.
From 1 June 2022, heel prick test also screens for muscle disease SMA, bringing number of screened diseases to 26 From 1 June 2022, the heel prick test for Dutch newborns will also screen for spinal muscular atrophy (SMA). SMA is a serious hereditary muscle condition. Detecting this disease at an early stage enables early treatment.